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Original citation: J Clin Invest. 2013;123(3):1371–1381. doi:10.1172/JCI66236. Citation for
this corrigendum: J Clin Invest. 2016;126(1):402–403. doi:10.1172/JCI84828. An error was
made during the preparation of Figure 6B, resulting in more lines on the graph than the
number of samples shown. In addition, the legend for Figure 6 did not indicate that WT plus
vehicle and WT plus PLX4720 samples shown in Figure 6B are also presented in Figure
6C. All samples in these panels were derived from the same set of experiments. The
authors have revisited the statistical analyses to account for the number of comparisons
appropriately. The corrected Figure 6 and sentences for the legend are below. Statistical
differences in tumor sizes between mice treated with vehicle and those treated with
PLX4720 therapy for each group were determined by a Kruskal-Wallis test with Dunn’s
correction (*P < 0.05; **P < 0.01). WT plus vehicle and WT plus PLX4720 samples shown in
B are also presented in C. All samples in panels B and C were derived from the same set of
experiments. Several panels in Supplemental Figure 4 for SM1 staining were accidentally
duplicated. The original raw data were reanalyzed and replotted and are shown in the
updated version of the supplemental data file. The PD-L1 panel for PLX4720 10 µM was
omitted in the corrected version, as there appeared […]
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An error was made during the preparation of Figure 6B, resulting in more lines on the graph than the number of samples shown. In addi-
tion, the legend for Figure 6 did not indicate that WT plus vehicle and WT plus PLX4720 samples shown in Figure 6B are also presented 
in Figure 6C. All samples in these panels were derived from the same set of experiments. The authors have revisited the statistical analy-
ses to account for the number of comparisons appropriately. The corrected Figure 6 and sentences for the legend are below.
Statistical differences in tumor sizes between mice treated with vehicle and those treated with PLX4720 therapy for each group were 
determined by a Kruskal-Wallis test with Dunn’s correction (*P < 0.05; **P < 0.01). WT plus vehicle and WT plus PLX4720 samples 
shown in B are also presented in C. All samples in panels B and C were derived from the same set of experiments.
Several panels in Supplemental Figure 4 for SM1 staining were accidentally duplicated. The original raw data were reanalyzed and replot-
ted and are shown in the updated version of the supplemental data file. The PD-L1 panel for PLX4720 10 μM was omitted in the corrected 
version, as there appeared to be a processing error with the original sample. The authors have stated that subsequent replicate experi-
ments are consistent with these findings.
The legend for Supplemental Figure 9A did not indicate that the WT plus vehicle and WT plus anti-CD137 plus vehicle groups shown are 
presented again in Supplemental Figure 9B. The online supplemental data file has been updated to correct this issue, and the statistical 
analysis has been revisited to account for the number of comparisons appropriately. None of the corrections alter the conclusions of the 
paper.
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The legend for Figure 9 did not indicate that the WT plus cIg plus vehicle and WT plus cIg plus PLX4720 groups shown are also presented 
in Supplemental Figure 7A. All samples in these panels were derived from the same set of experiments. The authors revisited the statisti-
cal analyses to account for the number of comparisons appropriately. Supplemental Figure 7 has been updated in the online supplemental 
data file. The corrected Figure 9 and sentences for the legend are shown below.
Statistical differences in tumor sizes between mice treated with anti-CD137 and those treated with combination therapy for each group 
were determined by a Kruskal-Wallis test with Dunn’s correction (**P < 0.01). The WT plus cIg plus vehicle and WT plus cIg plus PLX4720 
groups shown are also presented in Supplemental Figure 7A. All samples in Figure 9 and Supplemental Figure 7A were derived from the 
same set of experiments. 
The authors originally presented the same data in different panels for the sake of figure clarity and regret the subsequent confusion. The 
authors regret the other figure errors. 
Figure 9
Corrigendum
Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene
Joshua W. Knowles, Weijia Xie, Zhongyang Zhang, Indumathi Chennamsetty, Themistocles L. Assimes, Jussi Paananen, Ola Hansson, 
James Pankow, Mark O. Goodarzi, Ivan Carcamo-Orive, Andrew P. Morris, Yii-Der I. Chen, Ville-Petteri Mäkinen, Andrea Ganna, 
Anubha Mahajan, Xiuqing Guo, Fahim Abbasi, Danielle M. Greenawalt, Pek Lum, Cliona Molony, Lars Lind, Cecilia Lindgren,  
Leslie J. Raffel, Philip S. Tsao, The RISC (Relationship between Insulin Sensitivity and Cardiovascular Disease) Consortium, The 
EUGENE (European Network on Functional Genomics of Type Diabetes) Study, The GUARDIAN (Genetics UndeRlying DIAbetes in 
HispaNics) Consortium, The SAPPHIRe (Stanford Asian and Pacific Program for Hypertension and Insulin Resistance) Study,  
Eric E. Schadt, Jerome I. Rotter, Alan Sinaiko, Gerald Reaven, Xia Yang, Chao A. Hsiung, Leif Groop, Heather J. Cordell,  
Markku Laakso, Ke Hao, Erik Ingelsson, Timothy M. Frayling, Michael N. Weedon, Mark Walker, and Thomas Quertermous
Original citation: J Clin Invest. 2015;125(4):1739–1751. doi:10.1172/JCI74692.
Citation for this corrigendum: J Clin Invest. 2016;126(1):403. doi:10.1172/JCI85921.
Indumathi Chennamsetty’s name was spelled incorrectly in the author list. The correct author list is above.
The authors regret the error.
